Skip to content
lifestyle.californiaconsumerbanking.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Kowa Company Ltd.
New Drug Application for “K-911” Targeting Patients with Glaucoma and Ocular Hypertension Accepted for Filing in the U.S., Food and Drug Administration
August 27, 2026
Selective PPARα Modulator “K-808” (Pemafibrate) Granted “Breakthrough Therapy” Designation by the U.S. Food and Drug Administration (FDA) As a Treatment for Primary Biliary Cholangitis
June 30, 2026